NICE rejection

NICE rejects Enhertu for HER2-low breast cancer over cost concerns

NICE rejects Enhertu for HER2-low breast cancer over cost concerns

Anika Sharma

The remarkable efficacy data that initially earned AstraZeneca and Daiichi Sankyo’s Enhertu a standing ovation at the ASCO meeting last ...